CYP2C and IL-6 expression in breast cancer
Authors:
- R SchmidtRSR Schmidt
- D StanitzDSD Stanitz
- M BrauckhoffMBM Brauckhoff
- M SchönfelderMSM Schönfelder
- R PreissRPR Preiss
- 1 February 2004
- journal article
- Published by Elsevier in The Breast
- Vol. 13 (1) , 28-34
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamideJournal of Cancer Research and Clinical Oncology, 2002
- Tumour Cytochrome P450 and Drug ActivationCurrent Pharmaceutical Design, 2002
- IL-1 receptor type I expression in breast cancerThe Breast, 2001
- Expression, induction and regulation of the cytochrome P450 monooxygenase system in the rat glioma C6 cell lineBrain Research, 1998
- 27 Cytochrome P450 in normal human brain and brain tumoursBiochemical Society Transactions, 1997
- Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359allele as low-Kmcatalysts of cyclophosphamide and ifosfamide activationPharmacogenetics, 1997
- Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamideBiochemical Pharmacology, 1994
- Extrahepatic Metabolism of Drugs in HumansClinical Pharmacokinetics, 1994
- Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissueCarcinogenesis, 1990
- Metabolism of oxazaphosphorinesPharmacology & Therapeutics, 1988